Antiphospholipid syndrome (APS) is characterized by thrombosis or pregnancy complications associated with the presence of antiphospholipid antibodies (aPLs). Although the exact mechanisms are unclear, aPLs can increase the expression of tissue factor on platelets, leukocytes, and endothelial cells, leading to hypercoagulability. Extracellular vesicles (EVs) can also be released during this process and play a key role in immune regulation and thrombosis related to APS.
Aims
To evaluate the association between circulating levels of EVs and thrombosis related to APS, as well as inflammatory markers.
Methods
Case-control study including patients with thrombotic APS (t-APS) and healthy controls (HC). EVs expressing the following antigens were quantified by flow cytometry: CD41 (platelet integrin alpha IIb), CD162 (P-selectin glycoprotein ligand 1), CD31 (platelet and endothelial cell adhesion molecule 1), CD142 (tissue factor), and CD62 (P-selectin). EV levels were compared between groups and correlated with APS clinical and inflammatory parameters.
Results
A total of 69 t-APS patients and 46 HC were included. CD162+EV, CD31+EV, and CD41+EV levels were higher in t-APS patients compared to controls. CD41+EV levels were associated with venous thrombosis (p = .04) and multiple thrombosis (p = .07). Levels of CD162+EV, CD31+EV, CD142+EV and CD62P + EV were positively correlated with levels of interleukin-1 beta (IL-1β).
Conclusion
EVs expressing antigens related to platelet and endothelial cell activation and adhesion, as well as platelet-leukocyte interaction, were associated with thrombosis related to APS. The correlation between EV levels and IL-1β levels further underscore the association between EV release and thromboinflammatory responses in APS. Our results demonstrate the involvement of EVs in the interaction between inflammation and thrombosis in APS.
GardinerCHillsJMachinSJ, et al.Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus2013; 22: 18–25.
2.
CerveraRPietteJ-CFontJ, et al.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002; 46: 1019–1027.
3.
EspinosaGCerveraR. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol2010; 6: 296–300.
4.
ShiWChongBHChestermanCN. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood1993; 81: 1255–1262.
5.
WurmH. Beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem1984; 16: 511–515.
6.
MeroniPLRaschiETestoniC. Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. Autoimmun Rev2002; 1: 55–60.
7.
RiboldiPGerosaMRaschiE, et al.Endothelium as a target for antiphospholipid antibodies. Immunobiology2003; 207: 29–36.
ZaràMGuidettiGFCameraM, et al.Biology and role of extracellular vesicles (EVs) in the pathogenesis of thrombosis. Int J Mol Sci2019; 20: 2840.
10.
JamalySBasavarajMGStarikovaI, et al.Elevated plasma levels of P-selectin glycoprotein ligand-1-positive microvesicles in patients with unprovoked venous thromboembolism. J Thromb Haemostasis2018; 16: 1546-1554 DOI: 10.1111/jth.14162.
11.
VoukalisCShantsilaELipGYH. Microparticles and cardiovascular diseases. Ann Med2019; 51: 193–223.
12.
CampelloERaduCMSpieziaL, et al.Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles?Clin Chem Lab Med2017; 55: 934–943.
13.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis2006; 4: 295–306.
14.
BarionBGRochaTRFHoY-L, et al.Extracellular vesicles are a late marker of inflammation, hypercoagulability and COVID-19 severity. Hematol Transfus Cell Ther2024; 46: 176–185.
15.
TrummerADe RopCTiedeA, et al.Isotype controls in phenotyping and quantification of microparticles: a major source of error and how to evade it. Thromb Res2008; 122: 691–700.
16.
van der PolESturkAvan LeeuwenT, et al.Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation. J Thromb Haemostasis2018; 16: 1236–1245.
17.
HouJFuYZhouJ, et al.Lactadherin functions as a probe for phosphatidylserine exposure and as an anticoagulant in the study of stored platelets. Vox Sang2011; 100: 187–195.
18.
MesquitaGLTVYokoyamaAPHde SouzaCM, et al.Role of microvesicles as markers of inflammation and adverse clinical outcomes in orthotopic liver transplantation. Journal of Liver Transplantation2023; 9: 100138.
19.
SłomkaAUrbanSKLukacs-KornekV, et al.Large extracellular vesicles: have we found the holy grail of inflammation?Front Immunol2018; 9: 2723.
20.
ValkonenSMallasBImpolaU, et al.Assessment of time-dependent platelet activation using extracellular vesicles, CD62P exposure, and soluble glycoprotein V content of platelet concentrates with two different platelet additive solutions. Transfus Med Hemotherapy2019; 46: 267–275.
21.
VagidaMSArakelyanALebedevaAM, et al.Analysis of extracellular vesicles using magnetic nanoparticles in blood of patients with acute coronary syndrome. Biochemistry (Mosc)2016; 81: 382–391.
22.
BlairTAFrelingerAL. Platelet surface marker analysis by mass cytometry. Platelets2020; 31: 633–640.
23.
ŠtokUBlokarELenassiM, et al.Characterization of plasma-derived small extracellular vesicles indicates ongoing endothelial and platelet activation in patients with thrombotic antiphospholipid syndrome. Cells2020; 9: 1211.
24.
BreenKASanchezKKirkmanN, et al.Endothelial and platelet microparticles in patients with antiphospholipid antibodies. Thromb Res2015; 135: 368–374.
25.
VikerforsAMobarrezFBremmeK, et al.Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus2012; 21: 802–805.
26.
RodriguesTCRde Oliveira VazCMirandaECM, et al.Efficacy of a hypolipid diet in patients with primary antiphospholipid syndrome with dyslipidemia: a prospective study. J Thromb Thrombolysis2022; 53: 390–398.
27.
JyWTiedeMBidotCJ, et al.Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res2007; 121: 319–325.
28.
ChaturvediSCockrellEEspinolaR, et al.Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. Thromb Res2015; 135: 102–108.
29.
NiccolaiESquatritoDEmmiG, et al.A new cytofluorimetric approach to evaluate the circulating microparticles in subjects with antiphospholipid antibodies. Thromb Res2015; 136: 1252–1258.
30.
NagahamaMNomuraSKanazawaS, et al.Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in anti-phospholipid antibody syndrome. Autoimmunity2003; 36: 125–131.
31.
Flores-NascimentoMCBeltrameMPDe PaulaEV, et al.Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. Platelets2009; 20: 367–375.
32.
LertkiatmongkolPLiaoDMeiH, et al.Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr Opin Hematol2016; 23: 253–259.
33.
MullerWAWeiglSADengX, et al.PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med1993; 178: 449–460.
34.
VaporciyanAADeLisserHMYanHC, et al.Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science1993; 262: 1580–1582.
35.
CaligiuriG. CD31 as a therapeutic target in atherosclerosis. Circ Res2020; 126: 1178–1189.
36.
YangJFurieBCFurieB. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost1999; 81: 1–7.
37.
McEverRP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res2015; 107: 331–339.
38.
FalatiSLiuQGrossP, et al.Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med2003; 197: 1585–1598.
39.
KnightJSMengHCoitP, et al.Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. JCI Insight2017; 2: e93897–93897.
40.
HellLAyCPoschF, et al.Low extracellular vesicle-associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis. Ann Hematol2019; 98: 313–319.
41.
TobaldiniLQArantesFTSaraivaSS, et al.Circulating levels of tissue factor and the risk of thrombosis associated with antiphospholipid syndrome. Thromb Res2018; 171: 114–120.
42.
MazettoBMLazariniMTobaldiniLQ, et al.Expression of tissue factor mRNA in thrombosis associated with antiphospholipid syndrome. J Thromb Thrombolysis2021; 51: 370–378.
43.
WillemzeRBradfordRLMooberryMJ, et al.Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications. Thromb Res2014; 133: 187–189.
44.
XuJLasryJBSvarenJ, et al.Identification of equine P-selectin glycoprotein ligand-1 (CD162). Mamm Genome2005; 16: 66–71.
45.
LiberaleLHolyEWAkhmedovA, et al.Interleukin-1β mediates arterial thrombus formation via NET-associated tissue factor. J Clin Med2019; 8: 2072.
46.
PaiRZFangQTianG, et al.Expression and role of interleukin-1β and associated biomarkers in deep vein thrombosis. Exp Ther Med2021; 22: 1366.
47.
CambonARebelleCBachelierR, et al.Macrophage IL-1β-positive microvesicles exhibit thrombo-inflammatory properties and are detectable in patients with active juvenile idiopathic arthritis. Front Immunol2023; 14: 1228122.
48.
RidkerPMEverettBMThurenT, et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med2017; 377: 1119–1131.
49.
LacroixRJudiconeCMooberryM, et al.Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemostasis2013; 11: 12207. DOI: 10.1111/jth.12207.
50.
KnightJSKanthiY. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol2022; 44: 347–362.
